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High throughput screening (HTS) is the foundation of current drug discovery to assay drug
candidates for toxicity and biological effects (i.e. off-target and on-target responses, respecti-
vely). HTS is typically based on measuring thousands of drug candidates per day with a single
endpoint assay on a limited number of doses or even a single dose of compound. The assays
can be either based on absorbance or fluorescence measurements (i.e. Alamar Blue, MTT, Fluo-4
for calcium, etc.). Conversely, high content screening (HCS) is based on measuring a limited
number of drugs per day, but measuring up to eight different assays simultaneously with multiple
drug doses and even kinetic measurements. HCS assays typically are based on fluorescence
microscopy and automatic image analysis algorithms. With HCS technology, tedious and time
consuming assays can now be automated (i.e. nuclear size, micronucleus assay, lysosomal mass,
mitochondrial membrane potential, neurite outgrowth, etc.). Multi-channel FACS (fluorescence
activated cell sorting) can also be considered to be »high content« analysis. The purpose of this
















High Content Screening (HCS) is an advanced fluores-
cence microscopy technique utilizing sophisticated image
analysis algorithms to perform multiple bioassays simul-
taneously. As many as eight different assays can be per-
formed at the same time on live or fixed cells in various
well plates, using multiple fluorescent probes or endo-
genous fluorophores. Most HCS systems are essentially
an automated inverted fluorescent microscope with com-
puter control, some containing integral CO2 incubators
for monitoring live cells over entended intervals. Some
important bioassays for toxicology and drug discovery
applications include nuclear area, cytosolic calcium, mi-
tochondrial membrane potential, cell proliferation, cell
cycle, cell motility, oxidative stress, cell morphology, etc.
Mixed cell cultures can be measured with HCS methods
and the data for each cell type can be analyzed separa-
tely based on cell morphology. Labor intensive methods
such as the micronucleus assay, neurite outgrowth and
transcription factor translocation assays can be automat-
ed with HCS technology. Literally hundreds of distinct
assays are possible with antibody-based protocols. HCS
bioassay applications include research areas such as toxi-
cology, cancer, infectious diseases, CNS, cardiopulmo-
nary, and endocrine disorders. HCS assays are typically
based on primary cell or tumor cell cultures, but the
flexible HCS image analysis software can also measure
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fluorescently-labelled histology slides. HCS algorithms
allow the monitoring of specific organelles within cells,
allowing important drug mechanism information. Indivi-
dual cells can be monitored versus time, providing im-
portant sequence of events information for various cellular
parameters. By measuring multiple biomarkers simulta-
neously, several cellular mechanisms of toxicity can be
monitored at the same time providing drug safety pre-
dictivity data rivaling animal testing.1 Various HCS plat-
forms are available from several manufacturers, includ-
ing Becton Dickinson Biosciences, General Electric
Healthcare, Cellomics, Molecular Devices, etc.
CELL CULTURE
The most important reagent of in vitro assays is the cells
used for the assays, upon which the assays are based. Con-
sistent and careful cell culture is vital to in vitro assay
reproducibility. Strict adherence to cell culture protocols
is critical to consistent results (i.e. trypsinization methods,
serum levels, media type, etc.).
The choice of primary cells versus tumor cells or hu-
man cells versus animal in vitro models depends on the
end goal of the assay. Is the assay data intended to mo-
del human responses to drugs, or is the data to predict
animal responses to drugs to prioritorize drug candidates
for animal testing. Primary cells tend to have more me-
tabolic potential than tumor cell lines (i.e. cytochrome
P450 activity), valuable for metabolic assays or for com-
pounds which require metabolic activation for toxicity (i.e.
acetaminophen, diclofenac, etc.). However, primary cells
tend to have more inherent variability due to derivation
from distinct animal donors and often are actually a mix-
ture of cells types with differing characteristics (i.e. fi-
broblasts with muscle cells or periportal, perivenous and
Kupffer cell mixtures in hepatocyte isolations, etc.). Tu-
mor cells are by nature more consistent due to their clonal
expansion from a single cell. For example, the coefficient
of variation (i.e. 100  SD/mean) for acetaminophen IC50
values is 22.9 % for primary rat hepatocytes and only
6.0 % for HepG2 cells in the same WST-1 tox assay.2
The HCS toxicology results utilizing HepG2 cells as the
model has very good reproducible results for compound
IC50 values.
1 However, sub-clones of tumor cell lines can
occur after prolonged propagation, with altered biologi-
cal characteristics. It is recommended that cells be pro-
pagated to a limited extent beyond that obtained from the
supplier such as ATCC (i.e. a maximum of 20 passages
in the current laboratory). Frozen stocks of the cell lines
should be stored and regularly thawed/passaged.
Primary hepatocytes have been assumed to be more
sensitive cells than tumor cells for toxicology assays due
to their higher metabolic capability. However, hepatocytes
also loose metabolic capacity with time in culture, plus
hepatocytes are difficult and expensive to culture for
multiple days. HepG2 cells can have more sensitive IC50
values than hepatocytes if the assay is extended to three
days for the HepG2 cells. For example, the IC50 toxico-
logy values for several drugs are as follows: amiodarone,
38.3 ìmol dm–3 vs. 9.8 ìmol dm–3; chlorpromazine,
45.5 ìmol dm–3 vs. 6.4 ìmol dm–3; ketoconazole, 62.3
ìmol dm–3 vs. 62.2 ìmol dm–3; and quinidine, 244
ìmol dm–3 vs. 14.7 ìmol dm–3, for primary hepatocytes2
(one day incubation) and HepG2 cells1 (three days incu-
bation), respectively. Thus, tumor cells with longer incu-
bation times can produce more sensitive assay results
than primary cells. Tumor cell lines are much cheaper,
more convenient to propagate and store as frozen stocks
than primary cells as well.
Cell lines should be regularly assayed for bacterial
and mycoplasma contamination to prevent artifacts in the
assay results, an often overlooked, but important aspect.
Mycoplasma contamination could alter the normal bio-
chemistry of the cell lines and induce karytype changes
to the cells.3 The addition of antibiotics to culture media
(i.e. penicillin and/or streptomycin) typically inhibits bac-
terial growth. Primary cell lines can be prone to fungal
growth from hair or dander contamination, so agents
such as amphotericin may also be required. Rinsing the
animals with 70 % ethanol or detergent prior to tissue re-
moval can be useful to minimize microbial contamina-
tion to primary cell cultures. However, the effects of these
media anti-microbial compounds on the assays must be
considered (i.e. amphotericin generates pores in the plas-
ma membrane). Evaluation of test antibiotic compounds
effects on cells can be altered by the presence of similar
compounds in the culture media. Media antibiotics may
allow adaption of the cells to these class of compounds
and alter the responses of the test compounds in the as-
says. Control experiments with cell lines not adapted to
antibiotics should be considered for some compounds.
PLATE LAYOUT
The use of the outer wells of assay plates as valid data
sources needs to be considered carefully. The outer wells
tend to have the highest coefficients of variation and cell
growth tends to be inhibited relative to the wells in the
center of the plates. Idealists tend to exclude outer wells
from data analysis, with the loss of a major portion of
plate testing areas and decreasing assay throughput (i.e.
18–38 % decrease for 384 well and 96 well plates, res-
pectively). The outer wells often have the highest evapo-
ration rates and the high variation of outer wells results
is almost certainly due to increases of media osmolality
above physiological levels (i.e. 288 mmol/kg). For exam-
ple, the outer wells of a 96-well plate lose 34.8 % in vo-
lume and the inner wells lose only 16.7 % in volume over
a three day period in a humidified 37 °C incubator (see
Figure 1). Depending on plate design, even the outer
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wells can have large variations in evaporation rates. Cor-
ner wells can have high evaporation losses approaching
60 % in some cases, suggesting osmolality levels 250 %
of normal, certainly stressful to cells. These varying cul-
ture conditions between outer wells and inner wells can
have significant effects on assay outputs. A 25 % or more
increase of media osmolality (or decrease of media volu-
me) over the testing period can inhibit growth of some
cell types.1 The actual effect of hormesis or biphasic dose
response curves needs to be evaluated with unbias when
the effect is relative to outer control wells (i.e. increases
in cell growth at low compound doses). When doubt
exists, the testing should be repeated with the same drug
doses at the center of the plate where edge effects are
absent. Trend analysis on entire negative control plates
is a useful technique to determine the effect of edge
wells horizontally and vertically across the assay plate.
This trend data can be useful to design the plate layout
for reproducible assay results and valid conclusions be-
ing derived.4
CELL DENSITY
Cell density selection is an important consideration to
optimize signal-to-noise ratios. However, if tumor cell
lines are utilized, then the cell seeding density which pro-
duces a sub-confluent field of cells is often desirable to
prevent cellular metabolism senescence by cell-cell con-
tact inhibition. For HCS and imaging-based assays, over-
confluent cell densities complicates accurate focusing
since cells can be growing in several planes/layers. Ti-
tration of seeding density is recommended to determine
the optimum cell density for the particular assay condi-
tions at the specific time point. Cellular organelle cross
section areas are certainly inversely affected by cell cul-
ture densities. Nuclear diameter correlates inversely line-
arly with cell density after cells come into contact with
each other, but not at sub-confluent cell densities (unpub-
lished observations). Toxicology investigations utilizing
HCS techniques have shown that nuclear diameter is a
very robust and sensitive parameter to judge compound
effects on cells.1 Typically, nuclear diameter decreases
with increasing drug dose. However, if nuclear diameter
is biphasic with cell density, then the data is more com-
plicated to interpret. For example, if cell density is over
confluent, the nuclei are compressed and the toxic effect
of drugs to decrease cell numbers relieves this constraint
and nuclear size can initially increase, followed by a de-
crease in nuclear size at higher toxic compound doses.
Therefore, calculation of IC50 values in biphasic curves
are more complicated in over-confluent cell models. High
cell densities can also quickly deplete media nutrients as
well, complicating cell culture models. Cytosolic orga-
nelle cross sections are increased at lower cell densities,
making imaging these organelles much easier. However,
some primary cell lines prefer confluent cell densities, so
optimum cell density depends on the cell type and par-
ticular assay.
CULTURE SUBSTRATE
The selection of culture substrate is also a very impor-
tant factor to bioassay results. Many cell types prefer bio-
logical substrates which are more similar to their normal
environment (i.e. collagen I, collagen IV, fibronectin,
MatriGel, laminin, etc.). Cells can grow on plastic cell
culture surfaces (i.e. polystyrene), but there is some skep-
ticism whether the cell biology is normal. Moreover, dif-
ferent cell types prefer different culture substrates. Plas-
tics treated with plasma discharge can make the surfaces
with a positive charge more accommodating to the cells,
but still not natural. Poly-D-lysine (PDL) is often used
as a substrate since its poly-cation nature binds well to
the negatively charged phospholipids and carbohydrates
in cell membranes. The unnatural D-isomer polymer of
lysine seems to be less degraded by cellular proteases than
the L-isomer polymer. HepG2 cells tolerate PDL substra-
tes well, however, primary hepatocytes prefer collagen I
as a substrate and skeletal muscles prefer laminin.1,12,13
Non-native culture substrates may be more convenient
for assays, however, they may make cells more sensitive
to apoptosis or alter cellular biochemistry. It seems ac-
cepted that natural extra-cellular matrix (ECM) proteins
are optimal for cell growth, however, these materials tend
to be relatively expensive and can be slowly degraded by
the cells. Natural proteins can engage membrane recep-
tors and have anti-apoptotic and proliferative effects to
the cells.5,12 The choice of culture substrate may depend
on the length of the assay. Short assays of a few hours
may not be significantly affected by the growth substrate,
while assays lasting several days can be greatly affected
by the culture substrate. It is recommended that various
cell substrates be evaluated to find the optimal substance
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Figure 1. Outer wells versus inner wells evaporation. A 96-well
plate was loaded with 100 mL of media per well and incubated at
37 °C for three days at 90–95 % relative humidity and the volume
of all outer wells and all inner wells was determined.
for the particular assay and cell type. In some conditions,
mixtures of ECM proteins may be the most physiologi-
cal condition (i.e. MatriGel, co-culture with fibroblasts
to secrete ECM protein mixtures, etc.).
ASSAY CONDITIONS
Various assay parameters are important to minimize as-
say coefficient of variation and maximize reproducibility,
such as assay duration, dye concentrations, dye loading
times, washing protocols, temperature, etc. Sufficient as-
say dye concentration is required for optimum signal-to-
noise ratios, however dyes can alter cell physiology and
even be toxic to the cells (i.e. calcium dyes such as Fluo-4
AM bind calcium, altering free calcium levels and increas-
ing calcium diffusion rates). Excessive dye concentra-
tions can quench the signals of fluorescent dyes, actually
decreasing signal-to-noise ratios and causing difficult to
interpret dual response curves. This is particulary true of
Nernstian dyes which are accumulated in cells according
to the Nernst equation (defined by membrane potential
and dye concentrations terms).11 The dye TMRM is used
to monitor mitochondrial membrane potential and can be
concentrated up to 10 000 times the buffer levels inside
the mitochondria. The quenching limit for this dye is about
20 ìmol dm–3, therefore only nanomolar dye levels are
required for appropriate loading conditions. A decrease
in the TMRM signal is accepted as a toxicity marker at
controlled dye loading conditions. Excessive TMRM le-
vels can actually decrease the fluorescence signal due to
dye quenching. Titration of dye levels is recommended
for optimal responses and monitored kinetically with
control addition (i.e. mitochondrial uncoupler) to ensure
dye quenching is not occurring.6 Different cell types (i.e.
liver, heart, fibroblasts, etc.) may require different dye
levels due to dye metabolism, cell morpology or dye ex-
trusion by drug export pumps often upregulated in tumor
cell lines. Dyes can also have multiple responses depend-
ing on the concentration. It is reported that dihydroethi-
dium (DHE) monitors free radical production at concen-
trations below 1 ìmol dm–3 levels, however, the DHE
signal monitors mitochondrial membrane potential above
1 ìmol dm–3 levels.7 Relevant assay control compounds
are also important to verify that the parameter desired to
be monitored is actually being measured. Ionomycin is a
good acute non-fluorescent control compound for Fluo-4
calcium measurements. For example, FCCP is a proto-
nophore which serves as an excellent control compound
for mitochondrial membrane potential assays.12,13 An
initial increase in the TMRM signal after FCCP un-
coupler addition indicates dye de-quenching is occurring
and the cells are over-loaded with dye (see Figure 2a) and
the resulting dual-response data is not reliable. Figure 2b
shows cells properly loaded with TMRM, since the un-
coupler addition immediately causes a decrease in mito-
chondrial fluorescence, producing reliable results. Com-
pound absorbance and inherent fluorescence must also
be considered in the data analysis. Control experiments
must be designed to evaluate these effects on the final
results so that valid conclusions can be achieved.
Titration of the duration of the incubation time of the
compounds with the cells and the reporter dye loading
time can be very useful information to optimize responses
while minimizing detrimental effects of either reagent.
Longer incubation times of cells with drugs often tend to
increase assay sensitivity by lowering IC50 values, how-
ever it can also increase coefficient of variation values
due to the detrimental effects on the cells. Plotting assay
coefficient of variation and/or IC50 values versus com-
pound incubation time can be used to determine the opti-
mum assay time (i.e. low CV values and sensitive IC50
values). Also, for image-based assays, the number of fields
acquired per well is an important consideration. Too many
fields imaged is not efficient and decreases assay through-
put, but too few images can produce unacceptable assay
variability. Plotting assay coefficient of variation versus
fields imaged is very useful in determining the optimum
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Figure 2. Proper dye and dye over-loading conditions. Figure 2a
demonstrates cells over-loaded with TMRM by the addition of the
uncoupler FCCP induces an initial increase of fluorescence. Fig-
ure 2b demonstrates cells correctly loaded with the Nernstian dye
TMRM by the addition of FCCP causes an immediate decrease in
mitochondrial fluorescence.
amount of data to collect for a particular assay. Drug
toxicity can manifest itself by altering cell morphology
(i.e. cell rounding), which complicates image-based as-
says due to effects on focus accuracy vital to these meth-
ods. When to add compounds to the cells is an important
consideration. Adding the compounds to the cells within
a few hours of seeding them can save overall assay time.
However, the cells must be firmly attached to the culture
substrate before compound addition to ensure that the loss
of cell numbers is not merely due to interference of cell
adhesion rather than cytotoxicity. Overnight culturing of
cells before adding compounds increases assay times, but
allows the cells to recover from trypsinization or isola-
tion stresses (i.e. receptor degradation), helping to make
sure that the assay results are predominantly from the
compounds alone.
Reporter dyes can be photo-toxic to cells, so increas-
ed levels can increase signal levels but paradoxically de-
crease assay reliability or even to induce the event that
they are intended to measure. MitoTracker Orange used
to measure mitochondrial membrane potential can actual-
ly induce the loss of membrane potential at high loading
concentrations (i.e. the chlormethoxy moiety reacting with
key mitochondrial thiol proteins). Covalent membrane
potential dyes of this type do not measure continuously
and data must be analyzed accordingly to avoid invalid
conclusions being derived. For instance, initial labeling
of cells with covalent dyes will not measure subsequent
loss of membrane potential caused by added modulators.8
Several solvents are possible for organic fluorescent
dyes. Some of these solvents can modify assay results or
are not very compatible with biological systems, so care
must be taken to chose the solvent wisely. For example,
DMSO has anti-oxidant properties so may alter free ra-
dical assay responses and dimethylformamide is toxic to
some cell lines.1 The overall goal of assay optimization
is to maximize assay S/N ratios while also minimizing




Cells can adapt to stresses caused by culture conditions
or drug exposure by upregulating various drug transpor-
ters, cytochrome P450 isozymes, mitochondrial ATP
synthase, etc. Under conditions of respiratory chain in-
hibition, these mitochondria can still maintain a mem-
brane potential by the reverse action of the ATP synthase.
Detection of these mitochondrial defects by the TMRM
method require »sensitization methods« by inhibition of
the ATP synthase by the co-addition of oligomycin to
detect hidden mitochondrial pathologies.12
Drug inhibition of plasma membrane transporters such
as multi-drug resistance pumps (i.e. MDR, Pgp, etc.) or
organic anion transporters (i.e. OAT) can be utilized to
increase dye indicator levels inside cells. For instance, in-
hibition of OAT by probenicid aids in loading cells with
FURA-2 AM and cyclosporin H inhibits MDR pumps to
increase cell loading of TMRM. However, test compounds
can also inhibit these transporters and alter dye loading
of the cells (perhaps causing results misinterpretation),
causing dye quenching artifacts or increasing the photo-
toxicity of the dyes. Normalizing dye loading of cells
with transporter inhibitors (i.e. probenicid, verapamil,
reversin, etc.) is a possible method to keep dye levels in-
side cells constant from compound to compound.9 An
increase in assay signal with drug dose is not necessarily
a real response of the dye, but merely could be an in-
crease in the cellular dye concentration due to transporter
inhibition.11 Cyclosporin A and ketoconazole are excel-
lent inhibitors of MDR pumps and an increase in the
TMRM signal with dose is merely an increased cellular
accumulation of TMRM and not a true hormesis drug ef-
fect, an indicator of toxicity nor an indication of mito-
chondrial proliferation.1 In effect, TMRM is acting as an
MDR pump assay probe. TMRM signal intensity is strict-
ly a measure of mitochondrial membrane potential and
the presence of a true mitochondrial proliferation should
be verified by other methods (i.e. fixed mitochondrial
protein immunostaining such as cytochrome oxidase). In
fact, most increases in TMRM signal with drug dose
seems to correlate with their ability to inhibit drug trans-
porters. Some drugs require extended metabolism periods
in order to inhibit drug transporters and this effect of a
drug may not be present in acute drug exposure models.
Diaz et al. concluded that MDR inhibitors represent a
serious risk of error in the evaluation of mitochondrial
potential.16
COMPOUND TESTING CONCENTRATIONS
If IC50 values are to be utilized for assay outputs, then
the accuracy of the curve fitting will depend on the
concentrations tested. If the assay response is less than
50 % change of maximum, then inaccurate IC50 values
will be determined (i.e. poor sigmoidal curve definition).
For more accurate IC50 value calculations, one compound
dose which is above the IC50 value is recommended to
be tested. If the IC50 value is over 100 times the maximum
serum concentration (i.e. cmax), then no higher testing le-
vels is suggested for the sake of relevance. Dilution fac-
tor between doses is also an important consideration. A
dilution factor of 1:3 produces a wide range of dosing
concentrations with the same number of doses, however,
a lower dilution factor (i.e. 1:2) produces smoother curves,
perhaps with better correlation values.
If the assay is to cover multiple days, then re-dosing
the cells on a daily basis with compound needs to be
considered. Replacing drugs each day with fresh solu-
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tions may reflect regular patient dosing, however, it also
removes potentially important drug metabolites from the
media as well and increases the chances of cell layer de-
tachment the more physical manipulations of the assay
plates. Increased reagent, compound synthesis and labor
costs due to regular drug changes must also be consider-
ed. Adding media/nutrients to each well at day one suffi-
cient for multiple days of growth is an alternative me-
thod to ensure good cell culture for several day assays.
Drug serum concentrations vary widely by a factor
of a million or more for various drugs, from nanomolar
levels up to millimolar levels (i.e. 3 nmol dm–3 for tri-
fluoperazine and 1.65 mmol dm–3 for aspirin). Therefore,
a fixed dosing scheme for drug evaluations is not always
relevant to physiological drug concentrations in human
blood plasma. Some hormones (i.e. estradiol) can even
have picomolar plasma concentrations.1 For example, test-
ing a compound up to 100 mmol dm–3 would be 33,333
times the cmax (i.e. maximum serum concentration) value
for trifluoperazine and only 0.06 cmax for aspirin. There-
fore, trifluoperazine would be tested to many times its
normal levels and aspirin would be evaluated at a frac-
tion of its normal levels. A comparison of drugs to rank
toxicity would not be normalized or uniform with a fix-
ed dose testing scheme. Conversely, testing drugs to an
equal therapeutic index level (i.e. TI or testing concen-
tration / cmax value) would normalize drugs to the same
biological effect scale and make drug toxicity compari-
sons more standardized. A TI value of 30 or more could
be considered to be a safe drug, since a patient probably
would not achieve a dose 30 times the normal dose, except
during intentional overdose situations. Obviously, there
are exceptions where the TI of some currently marketed
drugs are five or less since there are no less risky drugs
available for serious conditions absolutely requiring treat-
ment (i.e. phenytoin, quinidine, etc.). These drugs typi-
cally require regular blood monitoring to ensure that toxic
doses are not being achieved in the patient. Testing drugs
to 30 times the serum levels is a guideline for safety eva-
luations, or where the cmax value is not available, testing
to 50–100 times the 50 % efficacy concentration (i.e.
EC50 value) for an in vitro efficacy assay might be con-
sidered. Some compounds are not soluble to these levels
in an aqueous system, so lower levels must be utilized in
some situations for practical reasons. For compounds with
high cmax values such as aspirin, millimolar levels of drug
are present and dilution of the osmolality down to iso-iso-
motic levels needs to be considered (i.e. 290 mmol/kg).
DMSO (dimethylsulfoxide) is utilized up to 1 % concen-
trations in assays, but this is equivalent to 141 mmol dm–3
levels and increases osmolality by 48 %. DMSO has been
reported to have anti-oxidant properties, so the effect of
this solvent on each particular assay is recommended (i.e.
free radical assays). Basic or acidic compounds can alter
the pH of culture media. Media pH after compound ad-
ditions should be tested and sterilely adjusted back to the
original media pH if significant deviations are measured,
or the inclusion of a good buffer such as HEPES to me-
dia should be considered.
The higher the top testing dose, the more likely drug
safety concerns are to be revealed and toxicity assays
tend to have more concordance with human clinical ex-
periences. HCS-based toxicity assays which utilized a test-
ing format of this type achieved concordance with human
toxicity for various target organs of about 70 % -results
rivaling animal testing responses. The toxicity of ceriva-
statin, a drug recalled from the market due to a number
of deaths, was revealed by every in vitro HCS assay uti-
lizing HepG2 cells as the model.1
IC50 VALUE RELEVANCE
A common method to express assay results is to present
the concentration at which there exists a 50 % change of
the range (i.e. IC50 value). This is a relatively typical meth-
od to characterize data curves using most graphics pro-
grams. In some cases the data is not sigmoidal in shape
or the full curve is not well defined, thus IC50 values are
not easy to calculate. However, in other cases a 50 %
change is an extreme one physiologically. For example,
only a 2.2 % change in serum osmolality levels is con-
sidered abnormal (typical range 282–290 mmol/kg), or
only a 0.04 change in blood pH is considered to be ab-
normal (typical range 7.36–7.44). When using Fluo-4 for
monitoring calcium levels, a 50 % change corresponds
to a calcium level of approximately 350 nmol dm–3, or
over four times the typical cytosolic levels of about
50–80 nmol dm–3 (i.e. the Kd of Fluo-4 is about 350
nmol dm–3).14 Sustained cytosolic calcium levels only
twice that of normal has been considered to be patholog-
ical.10 The IC50 value for a plasma membrane permeabil-
ity indicator (i.e. propidium iodide or TOTO-3) corre-
sponds to 50 % cell death, not a sensitive indicator of in
vitro cellular pathology. The coefficient of variation (i.e.
SD/mean) for an HCS nuclear size assay is very robust
(about 1–4 %). Therefore, a highly statistically signifi-
cant difference for nuclear area is only about a 15 %
change. Obviously, accepted statistical methods, such as
a student’s t-test to obtain p values, are recommended to
determine significance between control and test results,
plus biologically relevant changes need to be considered
to determine cut off limits for each particular assay. For
example, a cell count assay can have a coefficient of
variation of approximately 15 %. Therefore, a cell count
change of at least 30 % should be considered for a signi-
ficant change, or at a 95 % confidence level.1 Therefore,
more biologically relevant changes for each particular as-
say needs to be considered on an individual basis and an
IC50 value to determine toxicity may not be suitable for
every assay (i.e. IC50, IC30, IC15, etc. may be more ap-
propriate).
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The application of the Z ’ equation to evaluate the ro-
bustness of HTS assays is common, when only one or two
doses for each compound are tested and thousands of com-
pounds are tested each day. The Z ’ equation is Z ’ = 1 –
[(3  SD1 + 3  SD2) / (Mean1 – Mean2)], where SD1,
Mean1, SD2 and Mean2 are the standard deviations and
means of the high and low standards, respectively.15 This
equation implies that when Z ’ = 0 that the difference in
the means is an average of six standard deviations, a very
strict criteria when only a couple of doses are tested per
sample. However, in HCS assays, each well is often
measured multiple times and many doses are tested, pro-
viding more confidence and degrees of freedom in the
collected data (i.e. over a hundred data points define each
compound’s results). In assays which determine IC50 va-
lues, the number of doses, the correlation and standard
error of the resulting curve fit also provides confidence
in the data, whether it is reliable or not. Thus, for HTS
assays with only a few data points upon which to make
decisions, the very strict Z’ equation is often applied. How-
ever, in HCS assays which provide IC50 values derived
from dozens, or even hundreds of measurements, the Z ’
equation may not be applicable and the coefficient of va-
riation and curve fit statistics may be all that is required to
perform quality control of this data.
Compounds can have either cytostatic or cytotoxic
effects on cells (i.e. inhibition of cell growth versus actual
cell death, respectively). Cytostatic effects on cell growth
(i.e. inhibition of the cell cycle) primarily occurs in di-
viding cells such as tumor cells, peripheral blood mono-
nuclear cells (i.e. PBMCs), etc. Conversely, primary tis-
sue cultures have limited cell division (i.e. hepatocytes,
skeletal muscle, etc.). Tumor cells approximately double
in number every day in culture, while non-dividing cells
have relatively constant numbers with time. Therefore,
cell counts at 50 % of control wells in tumor cells could be
entirely due to cytostatic effects of drugs, while a 50 %
loss of cells in non-dividing cells is almost certainly due
to cytotoxic effects of compounds. Cytotoxic effects on
dividing cells is a decrease in the cell count below the
number of cells seeded at time zero. Data analysis has to
be considered based on these facts, whether the compound
is merely inhibiting cell growth or actually directly kil-
ling cells. Cell cycle analysis measurements are useful to
decide which event is predominating.
CONCLUSION
The previous discussion reveals that in vitro assay devel-
opment is a complicated and multi-factorial exploration
with many challenges. Multiple components of the entire
assay system need to be considered to produce a robust,
reproducible and reliable assay. Cell culture, cell type,
temperature, dye loading conditions, data analysis meth-
ods, drug dosing protocols, etc. must be carefully eva-
luated to produce accurate and dependable results.
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SA@ETAK
Biolo{ki obilje`iva~i u istra`ivanju novih lijekova: Va`ni ~imbenici prilagodbe pokusa
in vitro tehnologijama HTS i HCS
William A. Irwin, Dubravko Jeli} i Roberto Antolovi}
Tehnologija visokoproduktivnog probira (HTS, engl. High Throughput Screening) osnova je modernog is-
tra`ivanja lijekova, ~ime se uvelike ubrzava otkri}e novih aktivnih spojeva, ali i ispituju razli~iti toksi~ni i bio-
lo{ki u~inci ve} u ranoj fazi istra`ivanja. HTS se uglavnom temelji na mjerenju aktivnosti stotina ili tisu}a
spojeva dnevno – promatranjem samo jedne koncentracije ili ograni~enog broja razli~itih doza spojeva. Testovi
se uglavnom provode mjerenjem absorbancije ili fluorescencije. S druge strane, tehnologija visokosadr`ajnog
probira (HCS, engl. High Content Screening) temelji se na mjerenju manjeg broja spojeva dnevno, pri ~emu se
istovremeno mjeri nekoliko razli~itih biolo{kih testova u isto vrijeme uz razli~ite doze ispitivanih spojeva, uzi-
manjem u obzir ~ak i kineti~kih parametara. Automatizirani testovi HCS uglavnom ovise o fluorescencijskoj
mikroskopiji i automatiziranim algoritmima analize slika, ~ime se istovremeno mjere razli~iti parametri u sta-
nici poput veli~ine jezgre, mase lizosoma, mitohondrijskoga membranskog potencijala i sli~no. No, stani~ni
parametri mogu se uspje{no mjeriti i u mikrotitracijskim plo~icama od 96 ja`ica kori{tenjem razli~itih fluore-
scentnih obilje`iva~a ili endogenih fluorofora. Va`ni ~imbenici uspje{nih pokusa u ovom podru~ju jesu izbor
stani~ne kulture i odabir supstrata u kulturi, zatim uvjeti pokusa koji obuhva}aju raspored i koncentracije spoje-
va u ja`icama plo~ica, te na posljetku predvi|anje uvjeta u stanicama, poput uzimanja u obzir inhibicije trans-
portera lijekova. Razvoj stani~nih testova in vitro slo`en je proces koji ovisi o mnogim ~imbenicima. Samo
pa`ljiva priprema i odabir najboljih uvjeta za odre|enu metodu mo`e dovesti do kvalitetnog, reproducibilnog i
biolo{ki zna~ajnog stani~nog testa.
30 W. A. IRWIN et al.
Croat. Chem. Acta 81 (1) 23–30 (2008)
